@article{MTMT:36913927,
	title = {Obesity and autonomic dysfunction in schizophrenia: Associations with symptom severity and onset subtypes},
	url = {https://m2.mtmt.hu/api/publication/36913927},
	author = {Chang, Chun-Hung and Tsai, Hsin-Chi and Wu, Sheng-Nan and Tan, Han-Ru and Liu, Wen-Chun},
	doi = {10.1016/j.jpsychires.2025.09.025},
	journal-iso = {J PSYCHIATR RES},
	journal = {JOURNAL OF PSYCHIATRIC RESEARCH},
	volume = {191},
	unique-id = {36913927},
	issn = {0022-3956},
	abstract = {Background: Schizophrenia (SCZ) is associated with elevated cardiometabolic risk, including obesity and autonomic dysfunction. Reduced heart rate variability (HRV), reflecting impaired autonomic nervous system (ANS) function, is linked to increased mortality. Methods: Seventy inpatients with SCZ were evaluated using the Positive and Negative Syndrome Scale (PANSS). HRV was measured via a standardized 5-min protocol evaluating ANS balance, vagal activity (VAG), and standard deviation of normal-to-normal intervals (SDNN). HRV data from 112 age-matched healthy controls were included for comparison. Results: SCZ patients exhibited significantly reduced SDNN compared to controls (17.8 ms vs. 40.5 ms, p < 0.001). Older individuals with obesity exhibited higher HRV than younger, non-obese patients (SDNN: 27.8 ms vs. 14.3 ms, p = 0.019). Early-onset SCZ patients with BMI <24 showed higher PANSS-N (28.3 vs. 22.1, p = 0.012) and PANSS-G scores (41.0 vs. 35.9, p = 0.049) without HRV differences. Conversely, late-onset cases, especially among non-obese patients, was associated with better ANS and VAG indices (ANS: PCC = 0.643, p = 0.01; VAG, PCC = 0.581, p = 0.023). Males had higher white blood cell counts, while females with BMI <24 showed higher PANSS-N scores (p < 0.05). Use of long-acting injectable antipsychotics was linked to higher PANSS-S in non-obese patients (7.4 vs. 4.1, p = 0.036). Conclusion: Autonomic dysfunction is evident in SCZ, particularly in younger, non-obese individuals, and correlates with symptom severity and onset patterns. HRV and ANS metrics may serve as physiomarkers for risk stratification and personalized care.},
	keywords = {RISK; PREVALENCE; HEART-RATE-VARIABILITY; OBESITY; autonomic nervous system; heart rate variability; metabolic syndrome; METAANALYSIS; bipolar disorder; Antipsychotics; Psychopathology; Positive and Negative Syndrome Scale; NEGATIVE SYNDROME SCALE},
	year = {2025},
	eissn = {1879-1379},
	pages = {77-86},
	orcid-numbers = {Liu, Wen-Chun/0000-0001-9048-6363}
}

@article{MTMT:36273155,
	title = {Randomised active controlled trial examining effects of aerobic exercise, cognitive and music interventions on depression, balance and mobility in schizophrenia},
	url = {https://m2.mtmt.hu/api/publication/36273155},
	author = {Khanmohammadi, R. and Mirali, H. and Mohammadzadeh, H. and Ebrahimi, S. and Shaw, I. and Shaw, B.S.},
	doi = {10.1038/s41598-025-05024-x},
	journal-iso = {SCI REP},
	journal = {SCIENTIFIC REPORTS},
	volume = {15},
	unique-id = {36273155},
	year = {2025},
	eissn = {2045-2322}
}

@article{MTMT:36273154,
	title = {Comparative analysis of third-generation antipsychotics in first-episode schizophrenia: Efficacy, safety, and cognitive impacts. A narrative review},
	url = {https://m2.mtmt.hu/api/publication/36273154},
	author = {Ricci, V. and Sarni, A. and Martinotti, G. and Maina, G.},
	doi = {10.1097/YIC.0000000000000559},
	journal-iso = {INT CLIN PSYCHOPHARMACOL},
	journal = {INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY},
	volume = {40},
	unique-id = {36273154},
	issn = {0268-1315},
	year = {2025},
	eissn = {1473-5857},
	pages = {191-206}
}

@article{MTMT:34484128,
	title = {Multilevel evidence of MECP2-associated mitochondrial dysfunction and its therapeutic implications},
	url = {https://m2.mtmt.hu/api/publication/34484128},
	author = {Balicza, Péter and Gézsi, András and Fedor, Mariann and C. Sági, Judit and Gál, Anikó and Varga, Noémi-Ágnes and Molnár, Mária Judit},
	doi = {10.3389/fpsyt.2023.1301272},
	journal-iso = {FRONT PSYCHIATRY},
	journal = {FRONTIERS IN PSYCHIATRY},
	volume = {14},
	unique-id = {34484128},
	issn = {1664-0640},
	abstract = {We present a male patient carrying a pathogenic MECP2 p. Arg179Trp variant with predominant negative psychiatric features and multilevel evidence of mitochondrial dysfunction who responded to the cariprazine treatment. He had delayed speech development and later experienced severe social anxiety, learning disabilities, cognitive slowing, and predominant negative psychiatric symptoms associated with rigidity. Clinical examinations showed multisystemic involvement. Together with elevated ergometric lactate levels, the clinical picture suggested mitochondrial disease, which was also supported by muscle histopathology. Exploratory transcriptome analysis also revealed the involvement of metabolic and oxidative phosphorylation pathways. Whole-exome sequencing identified a pathogenic MECP2 variant, which can explain both the dopamine imbalance and mitochondrial dysfunction in this patient. Mitochondrial dysfunction was previously suggested in classical Rett syndrome, and we detected related phenotype evidence on multiple consistent levels for the first time in a MECP2 variant carrier male. This study further supports the importance of the MECP2 gene in the mitochondrial pathways, which can open the gate for more personalized therapeutic interventions. Good cariprazine response highlights the role of dopamine dysfunction in the complex psychiatric symptoms of Rett syndrome. This can help identify the optimal treatment strategy from a transdiagnostic perspective instead of a classical diagnostic category.},
	keywords = {mitochondrial dysfunction; anxiety; Rett syndrome; negative symptoms; cariprazine; learning disability; RNA sequencing; mecp2 mutation},
	year = {2024},
	eissn = {1664-0640},
	orcid-numbers = {Balicza, Péter/0000-0001-8555-5467; Gézsi, András/0000-0003-1022-6356; Fedor, Mariann/0000-0001-7926-0152; C. Sági, Judit/0000-0003-2186-9357; Gál, Anikó/0000-0002-2059-5748; Varga, Noémi-Ágnes/0000-0002-2064-5004; Molnár, Mária Judit/0000-0001-9350-1864}
}

@article{MTMT:34859218,
	title = {A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia},
	url = {https://m2.mtmt.hu/api/publication/34859218},
	author = {Selvan, P. and Devkare, P. and Shetty, A. and Dharmadhikari, S. and Khandhedia, C. and Mane, A. and Mehta, S. and Andrade, C.},
	doi = {10.3389/fpsyt.2024.1385925},
	journal-iso = {FRONT PSYCHIATRY},
	journal = {FRONTIERS IN PSYCHIATRY},
	volume = {15},
	unique-id = {34859218},
	issn = {1664-0640},
	year = {2024},
	eissn = {1664-0640}
}

@article{MTMT:34078666,
	title = {Cariprazine for negative symptoms in early psychosis: a pilot study with a 6-month follow-up},
	url = {https://m2.mtmt.hu/api/publication/34078666},
	author = {Pappa, S. and Kalniunas, A. and Maret, J.},
	doi = {10.3389/fpsyt.2023.1183912},
	journal-iso = {FRONT PSYCHIATRY},
	journal = {FRONTIERS IN PSYCHIATRY},
	volume = {14},
	unique-id = {34078666},
	issn = {1664-0640},
	year = {2023},
	eissn = {1664-0640}
}

@article{MTMT:32692122,
	title = {Real-life clinical experience with cariprazine: a systematic review of case studies},
	url = {https://m2.mtmt.hu/api/publication/32692122},
	author = {Csehi, Réka and Dombi, Zsófia Borbála and Sebe, B and Molnár, Mária Judit},
	doi = {10.3389/fpsyt.2022.827744},
	journal-iso = {FRONT PSYCHIATRY},
	journal = {FRONTIERS IN PSYCHIATRY},
	volume = {13},
	unique-id = {32692122},
	issn = {1664-0640},
	year = {2022},
	eissn = {1664-0640},
	orcid-numbers = {Molnár, Mária Judit/0000-0001-9350-1864}
}

@article{MTMT:33035980,
	title = {Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective},
	url = {https://m2.mtmt.hu/api/publication/33035980},
	author = {Morozov, P. and Bekker, R. and Bykov, Y.},
	doi = {10.3389/fpsyt.2022.868751},
	journal-iso = {FRONT PSYCHIATRY},
	journal = {FRONTIERS IN PSYCHIATRY},
	volume = {13},
	unique-id = {33035980},
	issn = {1664-0640},
	year = {2022},
	eissn = {1664-0640}
}

@article{MTMT:32183985,
	title = {Addressing negative symptoms of schizophrenia pharmacologically with cariprazine: evidence from clinical trials, a real-world study, and clinical cases},
	url = {https://m2.mtmt.hu/api/publication/32183985},
	author = {Németh, György and Dombi, Zsófia Borbála and Laszlovszky, István and Barabássy, Ágota},
	doi = {10.1080/14656566.2021.1968827},
	journal-iso = {EXPERT OPIN PHARMACO},
	journal = {EXPERT OPINION ON PHARMACOTHERAPY},
	volume = {23},
	unique-id = {32183985},
	issn = {1465-6566},
	keywords = {SCHIZOPHRENIA; psychopharmacotherapy; negative symptoms},
	year = {2022},
	eissn = {1744-7666},
	pages = {1467-1468}
}

@article{MTMT:32694111,
	title = {Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia},
	url = {https://m2.mtmt.hu/api/publication/32694111},
	author = {Rancans, Elmars and Dombi, Zsófia Borbála and Barabássy, Ágota},
	doi = {10.3389/fpsyt.2021.770234},
	journal-iso = {FRONT PSYCHIATRY},
	journal = {FRONTIERS IN PSYCHIATRY},
	volume = {12},
	unique-id = {32694111},
	issn = {1664-0640},
	abstract = {Although the optimal dosing of an antipsychotic medication is known to be essential in the long-term management of schizophrenia, in case of novel drugs such as cariprazine, determining the right dosing strategy is not that simple. Without decades of experience with a particular compound, evidence regarding dosing and titration comes primarily from double-blind, placebo controlled clinical trials that are not necessarily mirroring the real-life experiences of doctors. Via summarizing data from both clinical data (n = 3275) and real-world evidence (observational study n = 116, case studies n = 29), this perspective paper aims to shed a light on the appropriate dosing strategies of cariprazine from treatment initiation through switching strategies to concomitant medications.},
	keywords = {SCHIZOPHRENIA; SAFETY; DOUBLE-BLIND; Tolerability; Adherence; Antipsychotic; negative symptoms; cariprazine; ATYPICAL ANTIPSYCHOTICS; ACUTE EXACERBATION; medication; dosing; antipsychotic polypharmacy},
	year = {2022},
	eissn = {1664-0640}
}

@article{MTMT:33035975,
	title = {Using Cariprazine to Ameliorate Negative Symptoms and Metabolic Side Effects of Clozapine and Paliperidone-Clinical Cases},
	url = {https://m2.mtmt.hu/api/publication/33035975},
	author = {Viegas, Filipa and Ferreira, Tiago and Campos, Claudia},
	doi = {10.2147/NDT.S343747},
	journal-iso = {NEUROPSYC DISEASE TREAT},
	journal = {NEUROPSYCHIATRIC DISEASE AND TREATMENT},
	volume = {18},
	unique-id = {33035975},
	issn = {1176-6328},
	abstract = {Introduction: Cariprazine is a third-generation antipsychotic approved in Europe in 2017 for the treatment of schizophrenia. It presents distinct pharmacodynamic properties, such as D3/D2 partial agonism, preferential binding to D3 receptors, antagonism at the serotonin 5-HT2A and 5-HT2B receptors, partial agonism at 5-HT1A receptors, and low affinity to other receptors (including noradrenergic, histaminergic, and cholinergic). It has demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia with a safe side effect and metabolic profile. Methods: Here, we describe one clinical case of a patient that benefited from an add-on of cariprazine to a regimen of clozapine; and two clinical cases of patients that benefited from the switch from clozapine and paliperidone long-acting injectable to cariprazine. Results and Discussion: Those cases illustrate how cariprazine can be used in patients with schizophrenia in the treatment of both positive and negative symptoms, and when aiming to ameliorate the metabolic burden associated with other treatments. However, further studies are needed to consubstantiate those findings.},
	keywords = {SCHIZOPHRENIA; CLOZAPINE; paliperidone; cariprazine; Clinical Neurology},
	year = {2022},
	eissn = {1178-2021},
	pages = {1145-1149}
}

@article{MTMT:34078668,
	title = {Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment},
	url = {https://m2.mtmt.hu/api/publication/34078668},
	author = {Reznik, A.M. and Arbuzov, A.L. and Murin, S.P. and Pavlichenko, A.V.},
	doi = {10.17650/2712-7672-2020-1-2-43-51},
	journal-iso = {CONSORT PSYCHIATR},
	journal = {CONSORTIUM PSYCHIATRICUM},
	volume = {1},
	unique-id = {34078668},
	issn = {2712-7672},
	year = {2020},
	eissn = {2713-2919},
	pages = {43-51}
}